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Late gastrointestinal tissue effects after
hypofractionated radiation therapy of the
pancreas
Adnan Elhammali1, Mukund Patel2, Benjamin Weinberg3, Vivek Verma4, Jingxia Liu5, Jeffrey R. Olsen1
and Hiram A. Gay1*

Abstract
Background: To consolidate literature reports of serious late gastrointestinal toxicities after hypofractionated
radiation treatment of pancreatic cancer and attempt to derive normal tissue complication probability (NTCP)
parameters using the Lyman-Kutcher-Burman model.
Methods: Published reports of late grade 3 or greater gastrointestinal toxicity after hypofractionated treatment of
pancreatic cancer were reviewed. The biologically equivalent dose in 1.8 Gy fractions was calculated using the EQD
model. NTCP parameters were calculated using the LKB model assuming 1–5 % of the normal tissue volume was
exposed to the prescription dose with α/β ratios of 3 or 4.
Results: A total of 16 human studies were examined encompassing a total of 1160 patients. Toxicities consisted of
ulcers, hemorrhages, obstructions, strictures, and perforations. Non-hemorrhagic and non-perforated ulcers occurred
at a rate of 9.1 % and were the most commonly reported toxicity. Derived NTCP parameter ranges were as follows:
n = 0.38–0.63, m = 0.48–0.49, and TD50 = 35–95 Gy. Regression analysis showed that among various study
characteristics, dose was the only significant predictor of toxicity.
Conclusions: Published gastrointestinal toxicity reports after hypofractionated radiotherapy for pancreatic cancer
were compiled. Median dose was predictive of late grade ≥ 3 gastrointestinal toxicity. Preliminary NTCP parameters
were derived for multiple volume constraints.

Background
With an overall 5-year survival of 5 % and a 5-year survival of 20 % after surgical resection, pancreatic cancer
has an extremely poor prognosis [1]. It is the 9th most
common malignancy in the United States, but the 5th
most common cause of cancer-related death [2]. The aggressive nature of this cancer is partly due to its late presentation and the intimate anatomic relationship between the
pancreas and adjacent structures, namely the duodenum,
stomach, liver, bile ducts, spleen, and the great vessels
and their branches. Whether surgical, pharmacological,
or radiological, any pancreatic treatment must attempt
to preserve the integrity and function of these structures.
* Correspondence: hgay@radonc.wustl.edu
1
Department of Radiation Oncology, Washington University School of
Medicine, 4921 Parkview Place, Campus Box 8224, St. Louis, MO 63110-63110,
USA
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The only potentially curative treatment for pancreatic
cancer is surgical, although chemotherapy or chemoradiotherapy are often employed in the adjuvant setting
[3, 4]. Radiation therapy is also used in the setting of
unresectable disease for local control and symptomatic
palliation of pain and obstruction.
Conventionally fractionated treatments are lengthy,
may delay needed systemic therapy, and have not been
shown to be curative in unresectable disease. For these
reasons, hypofractionated schemes have sometimes been
employed, including stereotactic radiosurgery (SRS),
stereotactic body radiotherapy (SBRT), and intraoperative radiotherapy (IORT).
Because of its close anatomic association with the pancreas and its relative radiosensitivity, the small bowel
and stomach are the major dose-limiting organs in radiation treatment of the intact pancreas. Because of the
poor long-term survival of this patient population, acute
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side effects in the gastrointestinal tract are better characterized than late effects. The objective of this work
was to compile literature reports of grade 3 or greater
late toxicities in hypofractionated radiation treatment
of pancreatic cancer and attempt to derive normal tissue
complication probability (NTCP) parameters using the
Lyman-Kutcher-Burman (LKB) model [5].

Methods
Review criteria

A series of PubMed searches were performed looking
for English-language original articles that reported
gastrointestinal toxicity in humans following treatment
of pancreatic cancer with external beam radiation therapy. Over 200 papers fit our general search criteria, and
these were carefully screened for papers that reported
serious (grade 3 or above) late gastrointestinal complications from treatment with hypofractionated radiotherapy, without regard to technique. An attempt was made
to select papers with specific mention of duodenal toxicity, but we also included papers reporting late effects
in the stomach, small intestine, and other gastrointestinal organs. We also made an effort to avoid studies of
patients whose complications were reported in previous
publications. For the purposes of this review, late complications were considered to be those that occurred
after a minimum of 3 months of follow-up. The eligible
articles were published from 1981 to 2013.
Equivalent dose calculation and nomenclature

The biologically equivalent dose in f Gy fractions for a
total dose D Gy given in d Gy fractions using an r α/β
ratio is defined as:
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and represents the dose that if distributed evenly
across the volume, produces the same complication
probability as the actual dose distribution represented by
the summation. Variables vi and Di are the volume and
dose of each bin of the dose volume histogram (DVH).
Because the original DVH data was unavailable, hypothetical DVHs were constructed assuming 1–5 % of the
duodenum received the study’s prescribed dose while the
remaining volume received no dose. TD50 is the dose
that produces a 50 % complication probability if delivered uniformly to the organ. The variable m relates to
the slope of the integral of the normal distribution and n
denotes if the tissue is parallel or serial. Optimal solutions were obtained using the maximum likelihood
method by maximizing the following function:
X
lnL ¼
fðni −qi Þ lnð1−NT CP i Þ þ qi lnðNTCPi Þg;
i
such that ni represents the total number of patients and
qi the number of patients that developed complications
within bin i of radiation dose. The profile likelihood
method was then used to calculate 95 % confidence intervals for TD50, m, and n [6].
Statistical analysis

For example, 60Gy23 means a biologically equivalent
dose of 60 Gy in 2 Gy fractions using an α/β ratio of 3.
To simplify the comparison of different hypofractionated
schedules, we will use biologically equivalent doses defined in standard 1.8 Gy fractions, i.e.:

EQD1:8
r
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Linear regression model was used in univariate analysis
of toxicity rate. Variables of interest included median
follow-up, radiation dose level, number of dose fractions,
% of patients receiving chemotherapy, % of patients receiving surgery, and median overall survival. All statistical tests were two-sided using an α = 0.05 level of
significance. SAS version 9.3 (Cary, NC) was used to
perform the above statistical analysis.

Results
Study characteristics

NTCP LKB Model, Maximum likelihood fitting, and
confidence intervals

Normal tissue complication probity (NTCP) were calculated using the Lyman-Kutcher-Burman (LKB) model as
follows [5]:

A total of 16 human studies and two canine studies were
examined and are summarized in Tables 1 and 2 [7–24].
Two studies included characteristic and outcome data
for two separate cohorts and were therefore analyzed independently [19, 21]. The total number of patients
treated was 1160 with a median of 60 patients per study
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(range: 19–210). The median length of follow-up in
months among studies that reported a follow-up time
was 11.6 (range 3–28). The median EQD1.8
4 was 125 Gy
(range: 50–209).
Toxicity

Serious gastrointestinal toxicities consisted of ulcers,
hemorrhages, obstructions, strictures, and perforations.
The median late grade 3 or greater GI toxicity among all
studies was 7.4 % (range: 0–32.7 %). The most frequently
reported toxicity, with a median rate of 9.1 % (range:
3.9–20 %), was ulcers that were neither hemorrhagic nor
perforated. The highest rates of ulceration occurred in
the two cohorts of Nishimura and colleagues (9.9 % and
20 %) [20]. Not surprisingly, the median dose used in
these two cohorts was higher than any other study that
reported non-hemorrhagic and non-perforated ulcers
(EQD1.8
4 178 and 209, respectively). The patients in the
cohort that experienced a 20 % ulcer rate had resectable
tumors and underwent either pancreatectomy or pancreaticoduodenectomy, while the cohort with a 9.9 %
ulceration rate had unresectable tumors [20]. Hemorrhages, which consisted of hemorrhagic ulcers or erosions in the stomach, duodenum, or colon, occurred at
a median of rate of 4.6 % (range: 0.95–11.9 %). A median
of 3.6 % (range: 1.3–5.0 %) and 3.1 % (range: 0.60–5.2 %)
of patients developed perforations and strictures/obstructions, respectively.
There were four reported fatalities in the studies analyzed. Willett and colleagues reported two deaths from
treatment-related upper GI bleeding at 37 and 53 months
after treatment [18]. The patients in this study all received IORT, EBRT, and 5-fluorouracil with a median
EQD1.8
4 of 133 Gy. Okamoto and colleagues reported a
fatality 11 months after treatment from a hemorrhagic
ulcer in a patient that had undergone a distal pancreatectomy previously [21]. The exact dose used in this patient was not reported, but the median dose of the
cohort was 20 Gy IORT and 50 Gy EBRT postoperatively
(total EQD1.8
4 135 Gy). This study also reported a fatality
due to an esophageal variceal rupture 38 months after
treatment. This patient also underwent pancreaticoduodenectomy. The cause of death was deemed to be related to irradiation as the patient was found to have a
portal vein thrombosis and obstruction on CT scan.
Canine data

Toxicity rates from canine studies are summarized in
Table 2. Ahmadu-Suka and colleagues treated the abdomen of dogs with a single fraction IORT dose up to
40 Gy followed by 50 Gy of EBRT two weeks after surgery [23]. Dogs treated with 17.5 or 25 Gy IORT disease
(EQD1.8
4 126 and 177, respectively) showed mucosal atrophy, but did not show any duodenal ulcers on autopsy
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4.5 months after treatment. Dogs surviving greater than
3 months and treated with 32.5 Gy IORT (EQD1.8
4 256)
all showed ulcers on autopsy, and 25 % were perforated.
Among the dogs surviving longer than 3 months and
treated with 40 Gy IORT (EQD1.8
4 355), all experienced
duodenal ulcers, and 75 % were perforated.
Halberg and colleagues examined the duodenum of
dogs 6 months after treatment with 30 Gy IORT
(EQD1.8
4 176) in the presence of intraluminal WR-2721
or vehicle control [24]. The two dogs in the control cohort that survived to 6 months both showed grade 3
duodenal ulcers on autopsy.
NTCP model

Lyman NTCP model parameters and corresponding
95 % confidence intervals for human GI toxicity data are
summarized in Table 3. Because dose volume histograms
were not available, we estimated parameters assuming 1
to 5 % of the duodenum received the study’s prescribed
dose. If multiple doses or fractionation schemes were
employed in a single study, the median study dose was
used for our analysis. In some instances, the median
study dose was not provided and could not be calculated
because the exact dose distribution was not reported. In
these limited cases, the mean dose as reported by the
authors was used. According to published reports, an
α/β ratio of 3.0 or 4.0 is appropriate for bowel toxicity,
thus we estimated the median or mean EQD1.8
4 using a
α/β ratio of 3 or 4 (Table 3) [25, 26]. Figure 1 shows
overall GI toxicity rate as a function of median or mean
dose for each study and the maximum likelihood fit of
the LKB model for α/β ratio of 3 and 4 and duodenal
volume 1 % and 100 % (Fig. 1).
Univariate logistic regression

We performed univariate analysis to determine the effect
of follow-up time, dose, overall survival, primary modality of radiotherapy (SBRT vs. IORT), number of fractions, percentage of patients receiving chemotherapy,
and percentage of patients undergoing surgery on the
overall gastrointestinal toxicity rate. Dose was the only
significant predictor of GI toxicity (Table 4).

Discussion
Tissue complications from radiation therapy can present
in early and late phases. Early complications in the
bowel are related to acute mucosal injury. Denudation of
the rapidly dividing epithelial cells that line the gastrointestinal tract can result in nausea, vomiting, gastritis,
and/or diarrhea. These early effects are usually transient,
beginning less than a week after the first dose and resolving soon after the last treatment. Late complications,
on the other hand, may appear within a few months of
treatment and result from fibrotic changes to the bowel
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Table 1 Human GI toxicity rates from studies using hypofractionated radiotherapy for pancreatic cancer
EQD1.8
Chemo
4
(%)

Surgery
(%)

Late GI complications

30 Gy 3 fxa
(median)

72

86.1 %

None

GI bleeding requiring transfusion, grade ≥ 3 2/36 (5.6 %)

5.6 %

21

24 Gy 3 fxa
(median)

50

100 %

None

GI bleeding requiring transfusion, grade 3

7.7 %

Gastric outlet obstruction, grade 3

1/39 (2.6 %)

5.9

21 Gy 3 fxa +
50.4 Gyc
(median)

90

71 %

29 %

Bowel obstruction, grade 3

1/28 (3.6 %)

Gastric perforation, grade 3

1/28 (3.6 %)

25 Gy 1 fxa
(exact)

125

Biliary stricture, grade 3

2/77 (2.6 %)

Duodenal stricture, grade 3

1/77 (1.3 %)

Small bowel perforation, grade 4

1/77 (1.3 %)

Gastric ulcer, grade 3

3/77 (3.9 %)

Author
(reference)

N

Median
Radiotherapy
follow-up
(months)

Mahadevan
et al. [7]

36

24

Mahadevan
et al. [8]

39

Lominska et
al. [9]

28

Chang
et al. [10]

77

Hoyer
et al. [11]

22

6

3

30 Gy 5 fx
(median)

a

Chuong
et al. [12]

73

Schellenberg
et al. [13]

20

11.8

Didolkar et
al. [14]

85

Unknown 25.5 Gy 3 fxa
(median)

Polistina et
al. [15]

23

9

Rwigema et
al. [16]

71

Ogawa
et al. [17]

Willett
et al. [18]

10.5

45 Gy 3 fxa
(median)

25 Gy 1 fxa
(exact)

147

96 %

None

None

13.6 %

Complication
rate

Duodenum or stomach severe mucositisd
d

52

100 %

56 %

Duodenum or stomach ulceration

2/22 (9.1 %)

Stomach perforationd

1/22 (4.5 %)

GI bleeding requiring embolization, grade 3 3/73 (4.1 %)

9.1 %

22.7 %

5.5 %

Anorexia resulting in feeding tube
placement, grade 3

1/73 (1.4 %)

Duodenal perforation, grade ≥ 3

1/20 (5.0 %)

5.0 %

100 %

55

100.0 % 16.5 %

Late duodenitis (upper GI hemorrhage or
obstruction), grade ≥ 3

7/85 (8.2 %)

8.2 %

30 Gy 3 fxa
(exact)

72

100 %

None

Late GI toxicity, grade ≥ 3

0/23 (0 %)

0.0 %

12.7

24 Gy 1 fxa
(median)

116

90 %

39 %

Late GI toxicity, grade ≥ 3

0/71 (0 %)

0.0 %

210 26.3

25 Gy 1 fxb
(median)

125

54.3 %

100 %

GI toxicity unspecified, grade 3

3/210 (1.4 %)

3.3 %

Colitis, grade 4

1/210 (0.5 %)

GI bleeding, grade 4

2/210 (1.0 %)

20 Gy 1 fxb +
50.4 Gyc
(median)

133

100 %

82 %

Ileus, grade 4

1/210 (0.5 %)

Bleeding secondary to duodenal ulcer or
erosion requiring medical interventiond

16/150 (10.6 %) 15.0 %

Fatal duodenal bleeding, Grade 5

2/150 (1.3 %)

Duodenal obstructiond

1/150 (0.6 %)
d

Mohiuddin et 49
al. [19]

Nishimura et
al. [20]

2/22 (9.1 %)

7.1 %

125

150 17

None

2/39 (5.1 %)

Total GI
toxicity
rate

55

28

b

20 Gy 1 fx +
50 Gyc (median)

Unknown 26 Gy 1 fxb +
44 Gyc (mean)

133

178

100 %

34.2 %

None

100 %

Abdominal wall dehiscence

1/150 (0.6 %)

Otherd

2/150 (1.3 %)

Cholangitis, grade ≥ 3

2/49 (4.1 %)

GI bleeding, gastric antrum or
transverse colon, grade ≥ 3

3/49 (6.1 %)

Bowel obstruction, grade ≥ 3

2/49 (4.1 %)

Enteritis, grade ≥ 3

1/49 (2 %)

GI ulcer (non-perforating)d
Intestinal perforation

d

Abdominal abscessd
Ileus
29.3 Gy 1 fxb +
41 Gyc (mean)

209

27.4 %

None

2/55 (3.6 %)

2/55 (3.6 %)

GI ulcer (non-perforating)d
Intestinal perforation

32.7 %

3/55 (5.5 %)

d

71

11/55 (20.0 %)

16.3 %

d

7/71 (9.9 %)
2/71 (2.8 %)

19.7 %
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Table 1 Human GI toxicity rates from studies using hypofractionated radiotherapy for pancreatic cancer (Continued)
Abdominal abscessd

1/71 (1.4 %)

Duodenal fibrosisd

3/71 (4.2 %)

d

Okamoto et
al. [21]

Goldson et
al. [22]

Ileus

1/71 (1.4 %)

68

Unknown 20 Gy 1 fxb + 50
Gyc (median)

135

8.8 %

94.1 %

Duodenal ulcer, bleedingd

2/68 (2.9 %)

2.9 %

64

20 Gy 1 fxb + 50
Gyc (median)

135

None

100 %

Duodenal ulcer, fatal hemorrhagic shock,
grade 5

1/64 (1.6 %)

1.6 %

102

None

None

GI ulcers, bile duct obstructiond

2/19 (10.5 %)

10.5 %

19

Unknown 22.5 Gy 1 fxb
(median)

a

SBRT
IORT
c
EBRT
d
Grade not specified, but presumed to be a grade ≥ 3 toxicity
b

and its vasculature. Ischemia and fibrosis lead to mucosal
atrophy, ulceration, tissue breakdown, perforation, inflammation, and the formation of strictures, obstructions, and
adhesions. Perforation of the duodenum is particularly
dangerous due to its close proximity to the vessels of the
mesentery and their branches. Better characterization of
late gastrointestinal toxicity is important for safe treatment
of patients with pancreatic cancer.
In an attempt to characterize late GI toxicity in hypofractionated treatment of pancreatic cancer, we compiled
published gastrointestinal late toxicity data from multiple institutions. We reasoned that this approach, which
in total encompasses over a thousand patients across
multiple studies and institutions, would reveal gastrointestinal toxicity trends and patterns that may not be
apparent in studies with smaller cohorts. For example,
while ulcers were the most common observed toxicities
at a rate of 9.9 %, hemorrhages, perforations, and obstructions occurred at a rate of 3–5 % and might not be
appreciated in smaller studies.

We also examined the relationship between radiation
dose and late gastrointestinal complications. We specifically examined studies that used hypofractionated treatment irrespective of modality (between 1 and 5 fractions).
Several patients also received conventionally fractionated
radiotherapy. We calculated the EQD1.8
4 for all radiation
treatments given to the volume, and summed them arithmetically. Whether the linear-quadratic model accurately
represents the true biologic efficacy of hypofractionated
radiation treatments is an issue of debate, especially when
the fraction size is large [27]. In our analysis, we noticed a
clear relationship between dose and toxicity (Fig. 1). Univariate analysis of multiple study characteristics identified
dose as a significant predictor of toxicity (Table 4). A similar literature analysis attempting to identify a therapeutic
window for SBRT use in pancreatic adenocarcinoma by
Brunner and colleagues also identified a significant relationship between dose and gastrointestinal toxicity [28].
The authors compiled gastrointestinal toxicity from 16 literature reports following SBRT of the pancreas. Linear

Table 2 Canine GI toxicity rates from studies using hypofractionated radiotherapy
Author (reference) Nc Median follow-Up Radiotherapy
(months)
Ahmadu-Suka et
al. [23]

EQD1.8
Chemo Surgery Late GI complications
4
(%)
(%)

Complication Total GI
rate
toxicity rate

17.5 Gy 1 fxa + 50 Gyb
(exact)

126

none

100 %

0/4 (0 %)

0%

3

25 Gy 1 fxa + 50 Gyb
(exact)

177

none

100 %

0/3 (0 %

0%

4

32.5 Gy 1 fxa + 50 Gyb
(exact)

256

none

100 %

4

4.8

Non-perforated duodenal 3/4 (75 %)
ulcersd
Perforated ulcersd

a

4

Halberg
et al. [24]
a

2

40 Gy 1 fx + 50 Gy
(exact)

6

IORT
EBRT
c
Number of dogs surviving ≥ 3 months
d
Grade not specified
b

b

a

30 Gy 1 fx (exact)

355

176

none

none

100 %

100 %

100 %

1/4 (25 %)

Non-perforated duodenal 1/4 (25 %)
ulcersd
Perforated ulcersd

3/4 (75 %)

Duodenal ulceration,
grade 3

2/2 (100 %)

100 %

100 %
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Table 3 NTCP LKB parameters of pooled human GI toxicity
studies. An α/β ratio of 3 or 4, median or mean study EQD, and
duodenal volumes of 1–5 % were used for analysis. Parameters
and corresponding 95 % confidence intervals as calculated by
the profile likelihood method are shown
NTCP model
assumptions

NTCP model parameters

α/β

Volume

n (95 % CI)

3

1%

0.50 (0.47–0.53) 0.49 (0.46–0.52) 41.0 (36.2–47.4)

3

2%

0.38 (0.35–0.42) 0.49 (0.46–0.52) 91.0 (80.3–105.4)

3

3%

0.42 (0.38–0.46) 0.49 (0.46–0.52) 95.0 (83.9–110.1)

3

4%

0.50 (0.46–0.54) 0.49 (0.46–0.52) 81.9 (72.3–94.9)

3

5%

0.63 (0.58–0.67) 0.49 (0.46–0.52) 63.0 (55.6–72.9)

4

1%

0.48 (0.45–0.51) 0.48 (0.45–0.51) 39.0 (34.7–44.7)

4

2%

0.59 (0.56–0.62) 0.48 (0.45–0.51) 35.0 (31.1–40.1)

4

3%

0.45 (0.42–0.50) 0.48 (0.45–0.51) 71.0 (63.1–81.5)

4

4%

0.45 (0.42–0.50) 0.48 (0.45–0.51) 81.0 (71.9–92.9)

4

5%

0.43 (0.40–.48)

m (95 % CI)

TD50 (95 % CI)

0.48 (0.45–0.51) 95.0 (84.4–109.1)

regression showed a positive correlation between grade ≥ 3
toxicity and study EQD23 (R2 = .77). A 5 % rate of grade ≥ 3
toxicity was associated with an EQD23 of 80 Gy. Interestingly, examining the raw data for Fig. 1 based on a similar
EQD1.8
3 , the 5 % complication rate is reached at 80 Gy, and
with an EQD1.8
4 the 5 % complication rate is reached at
75 Gy. Therefore, both studies seem consistent in this
respect.
Because dose volume histograms were not available,
we estimated NTCP model parameters assuming duodenal volumes of 1–5 % received the prescription dose,
which is consistent with clinical practice and as reported
in some of the series we examined. For example, Chang

and colleagues as well as Schellenberg and colleagues
treated patients with 25 Gy in a single fraction using
SBRT. In both studies, the volume of duodenum receiving more than 22.5 Gy was less than 5 % [10, 13]. Willett
and colleagues as well as Goldson and colleagues
retracted normal GI structures away from the cylinder
applicator when treating patients with IORT [18]. Nishimura and colleagues similarly retracted normal GI structures outside the treatment field. In cases where the GI
structures could not be completely excluded, a smaller
dose was applied to the entire field and a higher dose
applied to the central region targeting the tumor (fieldin-field). Thus, an upper limit of 5 % of duodenal volume exposed to the maximum dose seems reasonable.
Derived NTCP LKB model parameters for the compiled toxicity data set are shown in Table 3. TD50 values
ranged from 35 to 95 Gy and represent clinically plausible constraints. Early work by Burman et al. analyzing
toxicity data compiled by Emami and colleagues obtained TD50 values of 55 for small intestine and 65 Gy
for stomach [29, 30]. Prior and colleagues attempted a
similar analysis on compiled duodenal and small bowel
toxicity using a modified linear quadratic model of multiple fractionation schedules and derived a TD50 value of
60.9 Gy [31]. Murphy and colleagues derived NTCP parameters for patients receiving a single 25 Gy dose using
SBRT for pancreatic cancer and obtained a TD50 value of
24.6 Gy (single fraction) [32]. Not surprisingly, our TD50
values were highly dependent on duodenal volume assumptions (Table 3). Indeed, Murphy and colleagues
performed a dose volume analysis of GI toxicity in patients treated with 25 Gy in a single fraction and found a
significant association between duodenal volume and
toxicity [32]. Availability of DVHs corresponding to

Fig. 1 Human late GI toxicity as a function of fraction corrected median or mean study dose (EQD1.8) for α/β of 3 (a) and 4 (b) and corresponding LKB
model assuming duodenal volume receiving the prescription dose of 1 % and 100 %. DV = duodenal volume

Elhammali et al. Radiation Oncology (2015) 10:186
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Table 4 Univariate analysis. The impact of several study
parameters on toxicity was analyzed using univariate analysis
Variable

P value

Median follow-up

0.82

Median radiation dose

0.01

Number of dose fractions

0.53

Modality (IORT vs SBRT)

0.29

% of patients receiving chemotherapy

0.22

% of patients receiving surgery

0.98

Median overall survival

0.53

toxicity would allow the prediction of more accurate and
clinically applicable NTCP parameters and highlights the
need for multi-institutional treatment toxicity databases.
While differences in treatment (i.e., use of chemotherapy
or surgery) or patient characteristics across institutions
may affect toxicity rates, our analysis suggests that dose
is the primary predictor of toxicity (Table 4). Other important and potentially confounding variables such as
median follow-up, median survival, use of chemotherapy, or surgery, were not significant.
There are many limitations to our approach. We examined the relationship of total dose to late GI toxicity
rate and did not study the relationship of dose to the
specific type of complication reported (e.g., ulceration,
bleeding, perforation). Many of the studies we analyzed
reported a range of doses given to their patient cohort,
and the majority did not report the specific dose corresponding to each reported toxicity. Thus, identifying
threshold doses for serious GI complications was difficult. To circumvent this limitation in reporting, median
study dose was used. This approach clearly has the potential to confound the relationship between radiation
dose and toxicity rate. Our analysis is also limited by the
lack of consideration of the variability in the partial volume of duodenum irradiated among different studies.
While we attempted to model the effect of partial volume by assuming uniform volumes of 1–5 % across all
studies, assuming a single volume for all studies will
likely introduce error. Differences among reporting strategies, modality, contouring of normal structures, and
general patient variability could all be sources of variability within the data. We attempted to identify sources
of variability within the data by performing univariate
regression analysis, which identified fraction-adjusted
dose as the only significant predictor of toxicity.

Conclusions
In conclusion, we have aggregated and analyzed late
gastrointestinal toxicity data from studies utilizing hypofractionated treatment for pancreatic cancer. Reported

toxicities consisted of ulcers, hemorrhages, obstructions,
strictures, and perforations. Non-hemorrhagic ulcers
were the most frequent complication and occurred in
approximately 9.1 % of patients. We also observed a relationship between study dose and rates of late grade ≥ 3
gastrointestinal toxicity and have derived preliminary
NTCP LKB model parameters. Additional studies using
individual patient data, with access to dose volume distributions and individual histories and toxicity reports,
would allow us to better characterize the dose–response
relationship for gastrointestinal toxicity in hypofractionated radiation treatment. A multi-institutional prospectively maintained treatment database would allow a
more accurate analysis to be performed in the future.
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